Literature DB >> 23788719

Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales.

Andrew B Rosenkrantz1, Sooah Kim, Ruth P Lim, Nicole Hindman, Fang-Ming Deng, James S Babb, Samir S Taneja.   

Abstract

PURPOSE: To compare the recently proposed Prostate Imaging Reporting and Data System (PI-RADS) scale that incorporates fixed criteria and a standard Likert scale based on overall impression in prostate cancer localization using multiparametric magnetic resonance (MR) imaging.
MATERIALS AND METHODS: This retrospective study was HIPAA compliant and institutional review board approved. Seventy patients who underwent 3-T pelvic MR imaging, including T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast material-enhanced imaging, with a pelvic phased-array coil before radical prostatectomy were included. Three radiologists, each with 6 years of experience, independently scored 18 regions (12 peripheral zone [PZ], six transition zone [TZ]) using PI-RADS (range, scores 3-15) and Likert (range, scores 1-5) scales. Logistic regression for correlated data was used to compare scales for detection of tumors larger than 3 mm in maximal diameter at prostatectomy.
RESULTS: Maximal accuracy was achieved with score thresholds of 8 and higher and of 3 and higher for PI-RADS and Likert scales, respectively. At these thresholds, in the PZ, similar accuracy was achieved with the PI-RADS scale and the Likert scale for radiologist 1 (89.0% vs 88.2%, P = .223) and radiologist 3 (88.5% vs 88.2%, P = .739) and greater accuracy was achieved with the PI-RADS scale than the Likert scale for radiologist 2 (89.6% vs 87.1%, P = .008). In the TZ, accuracy was lower with the PI-RADS scale than with the Likert scale for radiologist 1 (70.0% vs 87.1%, P < .001), radiologist 2 (87.6% vs 92.6%, P = .002), and radiologist 3 (82.9% vs 91.2%, P < .001). For tumors with Gleason score of at least 7, sensitivity was higher with the PI-RADS scale than with the Likert scale for radiologist 1 (88.6% vs 82.6%, P = .032), and sensitivity was similar for radiologist 2 (78.0% vs 76.5, P = .467) and radiologist 3 (77.3% vs 81.1%, P = .125).
CONCLUSION: Radiologists performed well with both PI-RADS and Likert scales for tumor localization, although, in the TZ, performance was better with the Likert scale than the PI-RADS scale. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13122233/-/DC1. RSNA, 2013

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23788719     DOI: 10.1148/radiol.13122233

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  88 in total

1.  Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter.

Authors:  Stephan H Polanec; Katja Pinker-Domenig; Peter Brader; Dietmar Georg; Shahrokh Shariat; Claudio Spick; Martin Susani; Thomas H Helbich; Pascal A Baltzer
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

2.  Prostate cancer: The applicability of textural analysis of MRI for grading.

Authors:  Frederick Kelcz; David F Jarrard
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

3.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

4.  Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.

Authors:  M C Roethke; T H Kuru; S Schultze; D Tichy; A Kopp-Schneider; M Fenchel; H-P Schlemmer; B A Hadaschik
Journal:  Eur Radiol       Date:  2013-10-03       Impact factor: 5.315

5.  Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.

Authors:  Gregory T Chesnut; Emily A Vertosick; Nicole Benfante; Daniel D Sjoberg; Jonathan Fainberg; Taehyoung Lee; James Eastham; Vincent Laudone; Peter Scardino; Karim Touijer; Andrew Vickers; Behfar Ehdaie
Journal:  Eur Urol       Date:  2019-12-23       Impact factor: 20.096

6.  Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience.

Authors:  S Demehri; A Belzberg; J Blakeley; L M Fayad
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-24       Impact factor: 3.825

Review 7.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

8.  Role of MRI for the detection of prostate cancer.

Authors:  Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George
Journal:  World J Urol       Date:  2021-01-04       Impact factor: 4.226

9.  The need for standardization of nuclear cardiology reporting and data system (NCAD-RADS): Learning from coronary artery disease (CAD), breast imaging (BI), liver imaging (LI), and prostate imaging (PI) RADS.

Authors:  Majid Assadi; Erik Velez; Mohammad Hosein Najafi; Ali Gholamrezanezhad
Journal:  J Nucl Cardiol       Date:  2018-10-29       Impact factor: 5.952

Review 10.  Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.

Authors:  Elmira Hassanzadeh; Daniel I Glazer; Ruth M Dunne; Fiona M Fennessy; Mukesh G Harisinghani; Clare M Tempany
Journal:  Abdom Radiol (NY)       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.